Terry and her colleagues have been researching the effect of natural medicine on MGUS & SMM patients for over a decade now. This work has been presented at conferences in Australia, Japan and the USA.
Below is a list of all her published work:
2020 - Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy.
2017 - Effect of the Ginger Derivative, 6-Shogaol, on Ferritin Levels in Patients With Low to Intermediate-1-Risk Myelodysplastic Syndrome-A Small, Investigative Study.
2017 - Evidence-Based Review of BioBran/MGN-3 Arabinoxylan Compound as a Complementary Therapy for Conventional Cancer Treatment.
2017 - Long-term follow-up of curcumin treated MGUS/SMM patients – an updated single centre experience.
2016 - Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
2015 - The effect of curcumin (as Meriva) on absolute lymphocyte count (ALC), NK cells and T cell populations in patients with stage 0/1 chronic lymphocytic leukemia.
2015 - Stabilisation of Laryngeal AL Amyloidosis with Long Term Curcumin Therapy
2013 - Curcumin enhances the cytotoxic and chemo-sensitising effects of lenalidomide in human multiple myeloma cells.
2013 - Long term use of curcumin in two smoldering multiple myeloma (SMM) patients.
2012 - Response to Vermorken et al--curcumin and free light chains.
2012 - Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
2011 - The impact of osteoporosis (as measured by lumbar spine quantitative computed tomography) on disease activity and survival in myeloma patients: a 13-year prospective study.
2010 - Vitamin D status may effect the skeletal complications of multiple myeloma.
2009- The potential role of curcumin in patients with monoclonal gammopathy of undefined significance – its effect on paraproteinemia and the urinary N-telopeptide of type 1 collagen bone turnover marker.